AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00497341
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
Trial: NCT03714776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching solution administered as SC injection.
Trial: NCT00404833
Drug: prednisolone and mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04306393
Drug: Nitric Oxide Gas
RxNorm normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively.
Trial: NCT00583011
Drug: Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Group: 2cc Normal Saline
Trial: NCT03315494
Drug: SKI-O-703 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKI-O-703 200 mg capsule with no inactive excipients.
Trial: NCT03315494
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 180 mg capsule filled with microcrystalline cellulose.
Trial: NCT03838029
Drug: Propranolol and etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A perioperative combined drug regimen
Trial: NCT00134758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day
Trial: NCT02394015
Drug: Trabectedin and Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
Trial: NCT02629042
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
Trial: NCT04281628
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
Trial: NCT03610880
Drug: TG-2349 (400 mg) plus DAG181 (200 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
Trial: NCT03610880
Drug: DAG181 (200 mg) plus TG-2349 (400 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
Trial: NCT00777062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection at the start of weeks 2 and 6.
Trial: NCT00652808
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks
Trial: NCT00652808
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks
Trial: NCT00080483
Drug: Testosterone plus somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
Trial: NCT00080483
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AndroGel transdermally 5 g a day for two years
Trial: NCT02469012
Drug: Combination #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir + Ribavirin
Trial: NCT02469012
Drug: Combination #2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir + Daclatasvir
Trial: NCT02469012
Drug: Combination #3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir + Daclatasvir + Ribavirin
Trial: NCT02469012
Drug: Combination #4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir + Ledipasvir
Trial: NCT02469012
Drug: Combination #5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir + Ledipasvir + Ribavirin
Trial: NCT02900664
Drug: TMT212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02900664
Drug: EGF816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03762681
Drug: RO7239958
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, subcutaneous use (SC).
Trial: NCT02373137
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Trial: NCT01119846
Drug: GSK1292263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
Trial: NCT01119846
Drug: GSK1292263 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to active drug GSK1292263
Trial: NCT02559570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Trial: NCT02559570
Drug: LIN Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Trial: NCT02559570
Drug: LIN Dose C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Trial: NCT02383355
Drug: Continuation of own regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation of own antiretroviral medication during the 10 weeks follow-up
Trial: NCT02766036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
Trial: NCT00001338
Drug: FLAC chemotherapy with GM-CSF
RxNorm normalized name: Flac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01219192
Drug: M2ES 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2ES 60mg IV D1,8,15,22 every 28days a cycle
Trial: NCT00736294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
Trial: NCT03279601
Drug: Capecitabine, Dacarbazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
Trial: NCT03279601
Drug: Capecitabine, Temozolomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
Trial: NCT02320448
Drug: PIPAC
RxNorm normalized name: Zagam Respipac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182830
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose
Trial: NCT02348008
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
Trial: NCT02348008
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Phase II Treatment: 200mg IV
Trial: NCT02453256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
Trial: NCT02370550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet 2-3 mg/kg/d, BID PO
Trial: NCT02370550
Drug: Calcium carbonate D
RxNorm normalized name: calcium carbonate / cholecalciferol Oral Tablet [Oysco D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbonate D 600 mg, QD PO
Trial: NCT02822157
Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
RxNorm normalized name: edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: physician's choice chemotherapy
Trial: NCT03816618
Drug: Hydrogel
RxNorm normalized name: HYDROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PURLOIN GEL
Trial: NCT03685500
Drug: Symtuza® (TAF/FTC/DRV/c)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
Trial: NCT03685500
Drug: ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
Trial: NCT02603510
Drug: SAR342434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Trial: NCT05204758
Drug: TCM Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three packages of TCM preparations with each meal three times a day
Trial: NCT00228410
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02688764
Drug: Calcium Acetate (Phoslyra®)
RxNorm normalized name: calcium acetate Oral Solution [Phoslyra]
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.
Trial: NCT01709409
Drug: BLES-group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 3 doses are administered to infants with RDS
Trial: NCT01306214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 10773 low dose
Trial: NCT01306214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 10773 high dose
Trial: NCT00219219
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01359020
Drug: ibuprofen, dipyrone, acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
Trial: NCT00864305
Drug: NEURONTIN® 400 mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Parke-Davis's marketed product
Trial: NCT03059537
Drug: Oral chenodeoxycholic acid stimulation
RxNorm normalized name: chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
Trial: NCT03188523
Drug: MK-8504
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
Trial: NCT00968708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin placebo matching tablets
Trial: NCT01170949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01031199
Drug: F-18 FEDAA1106 (BAY85-8101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
Trial: NCT02678728
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
Trial: NCT02186158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02372383
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anti-mycobacterial oral drug
Trial: NCT00329095
Drug: Additional ocular hypotensive medication
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00392756
Drug: gonadotropin releasing hormone (GnRH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
Trial: NCT03675971
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT02709109
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02709109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04605718
Drug: RO7223280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
Trial: NCT02483455
Drug: 2014-ALC-919-US
RxNorm normalized name: Drugs used in alcohol dependence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical solution to be applied twice daily for the treatment of Common Warts
Trial: NCT00259038
Drug: Carperitide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00259038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00888797
Drug: Propranolol and Etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
Trial: NCT04755894
Drug: HDDO-1756
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01462656
Drug: Non-EZG AED monotherapy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AED monotherapy without EZG
Trial: NCT01679028
Drug: T89 Group B
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg single dose
Trial: NCT03928379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01505231
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Trial: NCT01690299
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets BID
Trial: NCT01690299
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
Trial: NCT00201318
Drug: Cyclophosphamide Doxorubicin Vincristine Lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01556932
Drug: ABH gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT02710552
Drug: Tripliam (perindopril, indapamide, amlodipine)
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
Trial: NCT00776009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00323076
Drug: 18F-FAZA PET Imaging
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient.
Trial: NCT02066727
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline is administrated as an adjuvant of lidocaine.
Trial: NCT03610321
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
Trial: NCT03363893
Drug: CT7001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Trial: NCT03158610
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluorouracil
Trial: NCT00651144
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
Trial: NCT05471427
Drug: Taxane chemotherapy
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
Trial: NCT04233437
Drug: MLC1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLC1501 capsules (4 capcules (2000 mg) twice a day)
Trial: NCT04233437
Drug: CYP Cocktail
RxNorm normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
Trial: NCT04233437
Drug: Transporter Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
Trial: NCT00529178
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003896
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00100152
Drug: MK0752, (Notch Inhibitor)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04030234
Drug: Intensive BP treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
Trial: NCT04030234
Drug: Standard BP treatment group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Trial: NCT00944632
Drug: Placebo (vehicle ointment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily topical non-occlusive application for up to 4 weeks
Trial: NCT02888275
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01421992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet placebo per day during 3 weeks